Search

This reference book compiles together different animal models in cancer research. It provides knowledge and a better understanding of the advancement of the molecular and cellular mechanisms associated with the progression, formation, and clinical results of various types of cancer from the evidence collected from animal models utilized for cancer research. It discusses animal models for screening anti-cancer drugs and exploration of gene therapy. It presents different methods used to construct cancer animal models and the progress of each animal model in tumor research. The book also highlights the applications of genetic engineering, including CRISP/Cas9, in designing and developing animal models for cancer research. Further, it discusses strategies for modeling animals for investigating growth, metastasis, tumor-associated inflammation and microenvironment, cancer stem cells, tumor heterogeneity, and therapeutic resistance. This book is s a valuable resource for basic and translational cancer researchers, clinicians, and health care.

Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early-stage diagnosis. Molecular Targets and Cancer presents information about cancer diagnosis and therapy in a simple way. It covers several aspects of the topic with updated information on par with medical board levels. The book features contributions from experts and includes an overview of cancer from basic biology and pathology, classifications, surveillance, prevention, diagnosis, types of cancer, treatment and prognosis. The second part of this book discusses specialized topics in clinical oncology which include the pathophysiology of various types of cancer, cancer screening, different types of cancer surgery, cancer stem cell-targeted immunotherapy, nanotechnology for precision medicine applications in cancer and cancer surveillance. This comprehensive guide is a valuable resource for oncologists, researchers, and all medical professionals who work in cancer care and research.

This volume introduces the reader to the most important standards and principles of prophylactic surgery. After discussing the comparative effectiveness of screening in the treatment of hereditary cancer syndromes and evaluating genetic predisposition, the book moves on to address ethical, legal, social and cost-effectiveness dimensions of prophylactic surgery. With the aim of preventing hereditary predisposition syndromes, it also includes a chapter on the application of preventive surgery to all specific fields of surgery. Given its scope, the book will appeal to a broad readership, from experienced surgeons to students.

This book provides the most recent update on the management of neuroendocrine neoplasia (NEN), a term covering all tumors of various organs and/or with a particular histology, including MEN (multiple endocrine neoplasia) related tumors, MiNEN (mixed neuroendocrine-non-neuroendocrine neoplasms), NEC (neuroendocrine carcinoma) and Merkel's carcinoma. NENs are heterogeneous in their biology, clinical presentation and prognosis, showing a great variability in aggressiveness and therapy response. As a result, their treatment is based on a large spectrum of options. The standard therapies are surgery in early disease, various loco-regional procedures in certain conditions and mostly of a palliative nature in metastatic disease. At present, thanks to our increased understanding of molecular signaling pathways, several pharmacological approaches can be used in patients with advanced NENs. Somatostatin analogs display both anti-tumor effects and symptom control. Novel peptide-radio-receptortreatment (PRRT) is used in patients with well differentiated tumors. The agents targeting angiogenesis and/or PI3K/AKT/mTOR pathway, alone or in combination with analogues, have provided encouraging results in advanced disease. The first part of the book focuses on the history, epidemiology and the most relevant scientific achievements, covering the discoveries in genetic and molecular biology, the endoscopic techniques with guided biopsy, and the metabolic imaging with hybrid PET/CT and MRI/CT. It particularly highlights the emerging strategies in therapy, surgery and mini-invasive surgery as well as loco-regional and systemic treatments, including targeted therapy and/or biological therapies. The second part then explores the management of NENs of various anatomical origins and/or with peculiar biology. It describes the range of the current options and the most relevant results from the clinical trials. This informative book provides valuable insights for all thoseinterested in the management of neuroendocrine neoplasia.

Neuroendocrine neoplasms comprise a large family of proliferative lesions that involve almost every part of the body. Our understanding of their cells of origin as well as the pathology, pathophysiology and genetics of these neoplasms has made tremendous advances in the last few decades. While they are often discussed as separate entities in textbooks of gastroenteropancreatic pathology and pulmonary pathology, their scope is much broader. The book conveys the similarities and differences of these fascinating tumors that may be found from the hypothalamus and pituitary to the rectum, and in soft tissue as well as in many organs. Written by experts in the field, the authors emphasize their structural, functional, predictive and prognostic features and attempt to provide the clinical context that allows improved diagnosis and therapy while building on the genetics that clarifies patterns of inheritance and predisposition to tumor development through precursor lesions.The Spectrum of Neuroendocrine Neoplasia provides a broad overview of neuroendocrine neoplasms using a practical approach to diagnosis, histological classification and therapy, and presents the most important and significant developments of the technologies used to diagnose, classify and treat them.

The way a cell undergoes malignant transformation should meet their capacity of surviving in the microenvironment of the organ where the cancer will develop. Metabolic adaptation is for sure one of the criteria that must be accomplished, driven by metabolic plasticity that allows the adaptation of cancer cells to the availability of energy and biomass sources that will sustain cell survival and proliferation. Each human organ has a particular microenvironment which depends on several cell types and in some cases also on symbiotic microorganisms. These biological partners are constantly sharing organic compounds and signaling molecules that will control mitogenesis, cell death and differentiation, accounting for the organ's function. Nevertheless, cancer cells are capable of taking advantage of this metabolic and signaling microenvironmental dynamics.In this book, we intend to present the different components of the microenvironment driving the metabolic fitness of cancer cells. Themetabolic changes required for establishing a tumor in a given microenvironment and how these metabolic changes limit the response to drugs will generally be the major items addressed. It is important to mention not only aspects of the microenvironment that stimulate metabolic changes and that select better adapted tumor cells, but also how this regulation of cell plasticity is made. Thus, the signaling pathways that orchestrate and are orchestrated throughout this panoply of metabolic rearrangements will also be addressed in this book. The subjects will be presented from the conceptual point of view of the cross-cancer mechanisms and also particularizing some models that can be examples and enlightening within the different areas.

This book comprehensively describes the association between metabolic syndrome and pancreatic cancer progression, and the mechanism of action and target definition with a view to drug discovery. Metabolic syndrome, which includes adnominal obesity, hypertension, dyslipidemia, and hyperglycemia, has recently been shown to play an important role in the etiology and progression of various cancers. Further, obesity and diabetes have been associated with an increased incidence of gastric cancers. The book reviews the key biological mechanisms underlying the association between metabolic dysregulation, including obesity-associated enhancement of growth factor signaling, inflammation, and perturbation in pancreatic cancer cell growth and metastasis. It also illustrates the role of the inflammatory signaling pathway in metabolic diseases as well as tumor growth and explores the potential of these pathways as the rational targets for pancreatic cancer therapy. Lastly, the bookoffers a comprehensive description of the challenges associated with diabetes and pancreatic cancer therapy.

This book on neuroendocrine tumors (NETs) aims to present, in a clear and innovative manner, a broad topic that is still unevenly and in some respects poorly delineated. The novel feature is the nature of the focus on the principles of prognosis, diagnosis, and therapy, which are outlined on the basis of well-defined clinical scenarios described with the aid of high-quality images and illustrations. The salient observations to emerge from the reported clinical cases are clearly summarized, taking into account evidence from the literature and the available guidelines. All of the significant prognostic factors – histopathological, molecular, and imaging – and current diagnostic and therapeutic strategies for the major NETs (stomach, pancreas, ileum, appendix, bronchus) are covered. In addition, in the introductory part of the book the reader will find information on basic aspects including epidemiology, classification, and underlying biological mechanisms. Neuroendocrine Tumors inReal Life will be of interest to all specialists involved in the management of NETs; it will provide the experienced with important updates and equip trainees and students with a firm understanding of key concepts.

This book aims to equip readers with a better understanding of neuroendocrine tumors of the abdomen and explains how to manage them optimally by making use of novel therapeutic options that represent major advances on previous treatments. The most recent advances in epidemiology, genetics, molecular biology, biomarkers, pathology, diagnostics, clinical assessment, medical therapy, and surgical treatment are presented. The information and data provided will stimulate readers to develop their personal opinions on significant issues and assist in decision making in individual patients during routine clinical practice. The book features a multidisciplinary approach and is designed to meet the needs of all physicians seeking comprehensive guidance from experts on the management of patients with neuroendocrine tumors. It will also be of value for researchers wishing to acquaint themselves with the state of the art in the field and emerging research avenues. Abdominal Neuroendocrine Tumors is published in Springer's highly successful Updates in Surgery series, which now comprises more than 20 titles.

The second edition of Endocrine Surgery is a comprehensive update of the previous edition published in 2003. Edited by three leading authorities in the field of surgical endocrinology, the book encompasses the clinical, imaging, nuclear, molecular, technological and evidence-based principles that are applied in the diagnosis and treatment of all categories of endocrine tumors. Authored by experts from across the globe, this textbook reflects the best international clinical practice and also provides an outstanding educational resource. With full color illustrations throughout, the new edition emphasizes contemporary approaches in successive stages including: pituitary endocrine tumors; pathology and pathophysiology of pulmonary neuroendocrine cells; surgery of endocrine tumors of the lungs and thymus; robotic endocrine surgery; molecular testing of thyroid nodules; pediatric surgery for neuroblastoma and ganglioneuroma; multiple endocrine neoplasia; retroperitoneoscopic adrenalectomy; radionuclide imaging of carcinoid tumors, pancreas and adrenals; serotonin-induced cardiac valvular disease and surgical treatment; multimodal management of primary and metastatic neuroendocrine tumors; pathophysiology and surgery of Type II diabetes; post-bariatric surgery hyperinsulinemic hypoglycemia; and surgical management of metabolic syndrome. Endocrine Surgery 2e provides the clinician with a definitive resource to reach curative outcomes in the treatment of patients with endocrine pituitary, thyroid, and parathyroid entities. Further coverage of broncho-pulmonary, adrenal, pancreatic, and intestinal neoplasia is also included, making this the definitive textbook on the subject. Demetrius Pertsemlidis, MD FACS The Bradley H. Jack Professor of Surgery, Icahn School of Medicine at Mount Sinai, New York, USA William B. Inabnet III, MD FACS Professor of Surgery and Chief, Division of Metabolic, Endocrine and Minimally Invasive Surgery, Icahn School of Medicine at Mount Sinai, New York, USA Michel Gagner, M.D. FRCSC, FACS, FASMBS Clinical Professor of surgery, Herbert Wertheim School of Medicine, Florida International University, Miami, FL and Senior consultant, Hôpital du Sacre Coeur, Montreal, Quebec, Canada Print Versions of this book also include access to the ebook version.

The term ‘carcinoid'entered medical literature over 100 years ago to describe a peculiar intestinal epithelial neoplasm. Since then, a large body of literature has expanded the concept of carcinoid, later replaced by the term ‘NeuroEndocrine Tumor'(NET), defining a wide spectrum of peculiar tumors, potentially affecting all organs and tissues, originating from neuroendocrine cells, sharing, but, at the same time, keeping, pathognomonic pathological, radiological and clinical features. This book provides an authoritative overview of the epidemiological, clinical, genetic, molecular and pathological characteristics of NETs and highlights the most relevant controversial issues in the classification, diagnosis and therapy. Furthermore the new frontiers in the field of medical therapies are presented, through a multidisciplinary and translational approach. Considering the fact that NETs have been recently demonstrated less rare as considered so far,'Neuroendocrine Tumors: A Multidisciplinary Approach'is a must read for endocrinologists, gastroenterologists, endocrine surgeons, as well as pathologists, nuclear medicine physicians and radiologists focused on NET.

This textbook addresses themes ranging from the molecular issues of cancer sciences to clinical practice in medical oncology. It clarifies many topics, including molecular oncology, chemotherapy pharmacology and practical issues for clinicians. Systemic treatments in many areas of oncology feature, such as breast cancer, gastrointestinal, thoracic, urological oncology, head and neck tumors, bone tumors, sarcomas and palliative care.An excellent source for young physicians and researchers in the field of oncology, this book furthers understanding of medical oncology practice and facilitates professionals'treatment of cancer patients. It sets the direction for future research in the field, and will become the readers'regular working tool.

Dieses Buch informiert Ärzte, Pharmazeuten und alle weiteren in Heilberufen Tätige in schlagwortartigen Sätzen und mit Hilfe zahlreicher übersichtlicher Tabellen in leicht und schnell erfassbarer Weise über die Bestandteile und das Netzwerk des Immunsystems, seine Steuerung, seine Schutzfunktionen und über die von ihm ausgehenden Gefahren und Erkrankungen.Umfassend werden Grundlagen dargestellt der angeborenen und der erworbenen Immunabwehr und ihrer jeweiligen Reaktionswege des immunologischen Gedächtnisses und der Entwicklung einer Toleranz gegenüber körpereigenen Strukturen und in der Schwangerschaft der Wechselwirkung zwischen dem Nervensystem und dem Immunsystem, des Einflusses von Schlaf, körperlichen Tätigkeiten und Stress der Abwehr von Infektionserregern und Parasiten, die Lähmung dieser Abwehr und die Überreaktion bis hin zur Sepsis bzw. zum systemischen Immunreaktionssyndrom (SIRS) der Ursachen und Verlaufsformen von allergischen Erkrankungen und deren Behandlung der Autoimmunerkrankungen von einzelnen Organen (Nervensystem, Auge, Haut, endokrine Organe, innere Organe wie Lunge, Leber, Pankreas, Darm, Niere), des Kreislaufes und Herzens, des Blutes und des Bindegewebes, der Gelenke und der Muskulatur der Organabstoßung und deren medikamentöse Verhinderung der Tumorabwehr und der Beteiligung an Tumorerkrankungen der unterschiedlichen Arzneimittel zur gezielten Stärkung des Immunsystems (Impfstoffe, Antikörper gewonnen aus dem Blut oder biotechnisch monoklonal hergestellt, Wachstumsfaktoren, Zytokine, Interferone, Interleukine, biotechnisch hergestellte Derivate dieser Proteine) oder zur gezielten Hemmung des Immunsystems (Immunsuppressiva, blockierende Antikörper, blockierende Rezeptoren) Für jede durch die Immunabwehr verursachte Erkrankung erfolgt eine Beschreibung der Risikofaktoren, der ggfs. beteiligten Gene, der diagnostischen Verfahren, der Krankheitsstadien und der aktuellen Therapiemöglichkeiten.

Androgens are critical regulators of prostate differentiation and function, as well as prostate cancer growth and survival. Therefore, androgen ablation is the preferred systemic treatment for disseminated prostate cancer. Androgen action is exerted in target tissues via binding the androgen receptor (AR), a nuclear receptor transcription factor. Historically, the gene expression program mediated by the AR has been poorly understood. However, recent gene expression profiling and more traditional single-gene characterization studies have revealed many androgen-regulated genes that are important mediators of androgen action in both normal and malignant prostate tissue. This book will focus on the androgen-regulated gene expression program, and examine how recently identified androgen-regulated genes are likely to contribute to the development and progression of prostate cancer. Recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer will be included